Fosun International ( (HK:0656) ) has shared an update.
Fosun International Limited announced that the proposed merger by absorption of its subsidiary Henlius by Fosun New Medicine will not proceed as the required special resolution was not passed by Henlius’ shareholders. Despite this outcome, Fosun maintains its controlling interest in Henlius, which will continue to serve as a key platform for antibody technology without significant impact on Fosun’s operations.
More about Fosun International
Fosun International Limited is a conglomerate with its subsidiaries engaged in various industries including pharmaceuticals. It operates in the field of antibody technology, with Henlius being a significant platform for this sector within the Group.
YTD Price Performance: -0.73%
Average Trading Volume: 9,473
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $4.44B
See more insights into 0656 stock on TipRanks’ Stock Analysis page.